Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)
Date
2021-12
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Hanna, C R, O’Cathail, S M, Graham, J S, Saunders, M, Samuel, L, Harrison, M, Devlin, L, Edwards, J, Gaya, D R, Kelly, C A, Lewsley, L A, Maka, N, Morrison, P, Dinnett, L, Dillon, S, Gourlay, J, Platt, J J, Thomson, F, Adams, R A & Roxburgh, C S D 2021, 'Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)', Radiation Oncology, vol. 16, 230. https://doi.org/10.1186/s13014-021-01941-z